Vicapsys Life Sciences, Inc.
VICP
$1.77
$0.5039.37%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.10M | 1.08M | 1.04M | 1.03M | 659.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11M | 1.09M | 1.04M | 1.05M | 674.80K |
| Operating Income | -1.11M | -1.09M | -1.04M | -1.05M | -674.80K |
| Income Before Tax | -1.35M | -1.35M | -1.30M | -1.18M | -1.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.35 | -1.35 | -1.30 | -1.18 | -1.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.35M | -1.35M | -1.30M | -1.18M | -1.08M |
| EBIT | -1.11M | -1.09M | -1.04M | -1.05M | -674.80K |
| EBITDA | -519.40K | -687.00K | -814.90K | -1.02M | -643.60K |
| EPS Basic | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| EPS Diluted | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 135.57M | 135.64M | 136.77M | 139.28M | 135.50M |
| Average Diluted Shares Outstanding | 135.57M | 135.64M | 136.77M | 139.28M | 135.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |